Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese

Therapeutic Drug Monitoring

Volumn 29, Issue 1, 2007, Pages 118-121

  Goto, Shuji ^a   Seo, Takayuki ^a   Murata, Tsukasa ^a   Nakada, Naoyuki ^b   Ueda, Nao ^c   Ishitsu, Takateru ^d   Nakagawa, Kazuko ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

^c KUMAMOTO CHUO HOSPITAL   (Japan)

^d Kumamoto Saishunsou National Hospital   (Japan)

Author keywords

CYP2C9; Genetic polymorphisms; NONMEM; Phenobarbital

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID; ZONISAMIDE;

ADOLESCENT; ADULT; AGE; ARTICLE; BODY WEIGHT; CHILD; CONTROLLED STUDY; COVARIANCE; DRUG CLEARANCE; DRUG ELIMINATION; ENZYME POLYMORPHISM; EPILEPSY; FEMALE; GENDER; GENOTYPE; HUMAN; INFANT; JAPANESE; MAJOR CLINICAL STUDY; MALE; POPULATION; PRIORITY JOURNAL; SCREENING; STEADY STATE;

ADULT; ALGORITHMS; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG MONITORING; EPILEPSY; FEMALE; GENE FREQUENCY; GENETICS, POPULATION; HETEROZYGOTE; HOMOZYGOTE; HUMANS; IMMUNOASSAY; ISOXAZOLES; JAPAN; MALE; METABOLIC CLEARANCE RATE; MIXED FUNCTION OXYGENASES; PHENOBARBITAL; PHENYTOIN; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; VALPROIC ACID;

EID: 33847137375     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318030def0     Document Type: Article

References (12)

1. Kwan P, Brodie MJ. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia. 2004;45:1141-1149.
2. Wang WZ, Wu JZ, Ma GY, et al. Efficacy assessment of phenobarbital in epilepsy: a large community-based intervention trial in rural China. Lancet Neurol. 2006;5:46-52.
3. Anderson GD. Phenobarbital and other barbiturates: chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002.
4. Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology. 2004;63(Suppl 4): S3-S8.
5. Mamiya K, Hadama A, Yukawa E, et al. CYP2C19 polymorphism effect on phenobarbitone: pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol. 2000;55:821-825.
6. Hadama A, Ieiri I, Morita T, et al. P-hydroxylation of phenobarbital: relationship to (s)-mephenytoin hydroxylation (CYP2C19) polymorphism. Ther Drug Monit. 2001;23:115-118.
7. Richards B, Skoletsky J, Shuber AP, et al. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet. 1993;2:159-163.
8. Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics. 1997;7:405-409.
9. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther. 1996;60:661-666.
10. de Morais SMF, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269:15419-15422.
11. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005;77:1-16.
12. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997;7:59-64.